Retinoblastoma is the most common primary intraocular tumor in childhood. Mutations in both the alleles of the RB1 gene represent the causative agent for the tumor to occur. It is becoming evident that, although these alterations represent key events in the genesis of retinoblastoma, they are not sufficient per se for the tumor to develop, and other additional genetic or epigenetic alterations must occur. A supportive role in the genesis of retinoblastoma has recently been proposed for the RB1-related gene RB2/ p130. Additionally, several other genetic alterations involving different chromosomes have been described as relevant in the tumorigenic process. In this review we will analyse current knowledge about the molecular mechanisms involved in retinoblastoma, paying particular attention to the mechanisms of inactivation of the biological function of the retinoblastoma family of proteins.
Introduction
The fact that inherited abnormalities predispose some individuals to cancer was first hypothesized more than one century ago, but only in the past 20 years has it been possible to identify several genes responsible for tumorigenesis (Li-Fraumeni syndrome). Cancer may be considered a genetic disease, occurring when normal cells progressively transform through the acquisition of mutations in the genome. When this happens, cells continue to proliferate independently of regulatory influences that control cell growth, whose regulation depends on negative and positive growth signals. Negative regulation is exerted by a family of genes known as tumor suppressors, which regulate cell growth and homeostasis. The proto-oncogenes, whose function is to promote cell proliferation, carry out positive regulation of cell growth. It has become increasingly evident that cancer is a genetic disease, requiring alterations of tumor suppressor genes and protooncogenes that may occur if genomic integrity is compromised owing to intrinsic factors or exogenous agents. The mechanisms of inactivation of tumor suppressor genes and proto-oncogenes are different: tumor suppressors are inactivated by 'loss of function mutations', whereas proto-oncogenes are activated through 'gain of function mutations'. Tumor suppressors are functionally inactive in cancer cells, thus determining the loss of control over cell proliferation; on the other hand, proto-oncogenes are constitutively activated, leading to continuous signaling which acts positively on cell growth. The different mechanism of inactivation means that when cancer depends on the inactivation of a tumor suppressor gene, both the alleles of the tumor suppressor gene must be inactivated for the tumor to occur, even though several lines of evidence indicate that this is not true in the case of haploid insufficiency. Proto-oncogene-driven transformation, on the contrary, requires the mutation of a single copy of the proto-oncogene which then becomes activated, leading cells toward transformation.
The first tumor suppressor identified was RB1 (the retinoblastoma susceptibility gene), mutations of which are responsible for a childhood retinal malignancy, the retinoblastoma (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987a, b) . The importance of hereditary factors for the occurrence of this pediatric cancer has been evident since 1821, when a familial aggregation of retinoblastoma was observed (Kaelin, 1955) . Initially, all cases were considered to be inherited diseases, but it subsequently became clear that there were non-inherited forms of retinoblastoma (Vogel, 1954) . The problem was unraveled in 1971, when Knudson postulated a model to explain the different origins of hereditary and non-hereditary retinoblastomas, much earlier than cloning of the causative gene took place.
Retinoblastoma: the pediatric tumor
Retinoblastoma is a rare malignant tumor of the eye that originates in developing cells of the retina. It has an incidence of 1 in 20 000 live births in all human races (Suckling et al., 1982) , and does not vary according to geographical location or level of industrialization. Diagnosis is possible on the basis of clinical symptoms, usually within the first 5 years of age. Only 10% of affected children have a familial history of retinoblastoma, therefore most of the time the tumors are discovered when one or both eyes are already full of tumor, giving the pupil a 'cat's eye' appearance due to a white papillary reflex (leukocoria) which may be accompanied by strabismus. Retinoblastoma occurs in both hereditary and nonhereditary forms: the hereditary form accounts for 40% of patients and demonstrates an autosomal dominant inheritance; patients have retinoblastoma in both eyes (bilateral retinoblastoma), often showing more than one focus per eye (bilateral multifocal retinoblastoma) and a lifelong predisposition to cancer throughout the body (Onadim et al., 1992) . About 60% of patients have retinoblastoma in only one eye (unilateral retinoblastoma) and this represents a sporadic disease, as there is no family history for this cancer. Nonhereditary retinoblastoma consists of a unifocal retinal tumor and involves no increased risk of other cancers. Mutations of both the alleles of the RB1 gene are necessary for the disease to occur (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987a, b) . In patients with sporadic unilateral retinoblastoma, the two RB1 mutations that initiate tumor development are somatic events and therefore they cannot be inherited, and none of them are present in DNA from constitutional cells (Shimuzu et al., 1994; Lohmann et al., 1997; Klutz et al., 1999) . Patients affected by bilateral retinoblastoma are heterozygous for an RB1 mutation, which was either inherited or occurred de novo in parental germline cells or during embryonal development. During early childhood, these patients are predisposed to retinoblastoma because a mutation in the wild-type allele will lead to biallelic inactivation of the RB1 gene, thereby initiating the development of the tumor focus. In most families with retinoblastoma, all members who have inherited a mutation develop bilateral retinoblastoma. However, in some exceptional families unilateral retinoblastoma is frequent and some mutation carriers remain unaffected (low-penetrance retinoblastoma). In addition to retinoblastoma, carriers of an RB1 mutation also show a high incidence of other tumors that are collectively known as second primary neoplasms. These include bone and soft tissue sarcomas, malignant melanoma and neoplasms of the brain and meninges (Eng et al., 1993) . Diagnosis of patients with bilateral retinoblastoma is made earlier than patients with unilateral retinoblastoma (11 and 22 months, respectively). Compared to other solid tumors, retinoblastomas are small at the time of the diagnosis and can be successfully treated in more than 95% of cases (de Sutter et al., 1987) , although patients still require constant lifelong follow-up for early detection of recurrent tumors or detection of secondary tumors (for a review about diagnosis and treatment of retinoblastoma, see Balmer et al., in this issue).
Molecular basis of retinoblastoma
Light was shed on the molecular mechanisms underlying retinoblastoma development when Knudson proposed a model to explain the difference between hereditary and nonhereditary forms in 1971. This model, referred to as the 'Two-hit hypothesis', highlights that the phenotypic difference between these two forms of retinoblastoma may be explained by different molecular mechanisms. For the tumor to occur inactivation of both the alleles of the RB1 gene is necessary, but there is a different mechanism for this inactivation. Knudson hypothesized that heritable retinoblastoma tumors depend on a RB1 gene mutation, which occurs in germinal cells and can therefore be inherited. Although this first mutation (M1) renders people susceptible to cancer, in not sufficient per se for the tumor to develop. In fact, the normal allele still provides the required function of RB1 in the constitutional cells, in subjects carrying a germline RB1 mutation. Tumors will occur only when an additional, somatic mutation (M2) arises in retinal cells in the second copy of the gene (the second hit), thus inactivating the function of the RB1 gene. In nonhereditary retinoblastoma, both the events are supposed to be somatic (Knudson, 1971; Knudson et al., 1973) . The incidence of nonhereditary forms depends upon a first somatic mutation in the developing retina, growth of the mutant clone, and a subsequent mutation in one cell of that clone. This explains the high incidence of bilateral tumors in patients carrying germline mutations, and the younger ages at first appearance of tumor. In most hereditary forms, there are new germinal mutations and both parents are normal. In the hereditary forms, therefore, M1 occurs in the germinal cells, whereas M2 occurs in a retinal cell; in nonhereditary tumors both M1 and M2, which inactivate both the RB1 alleles, must arise in the same retinal cell (Figure 1 ). Almost all kinds of RB1 mutations have been described, including point mutations, insertions, deletions, translocations (for a review, see Lohmann, 1999) . In addition, epigenetic events such as promoter hypermethylation have been described as causative agents for RB1 functional inactivation (Sakai et al., 1991; Zeschnigk et al., 1997; Choy et al., 2002) . In this review, we will summarize the current knowledge about retinoblastoma, with particular emphasis on the retinoblastoma family of proteins, in order to understand the molecular mechanisms underlying the disease.
RB1: the gene and the protein structure
The RB1 gene consists of 27 exons scattered over 180 kb at chromosome 13q14 (Toguchida et al., 1993) . The gene is transcribed in a 4.7 kb messenger RNA (Lee et al., 1987b) , whose open reading frame of 2.7 kb encodes a ubiquitously expressed protein of 928 residues (Lee et al., 1987a) . This protein migrates as a 110 kDa phosphoprotein (Lee et al., 1987a) , often referred to as pRB 110 (pRb/p105), which has two paralogues, pRb2/ p130 and p107, with which it constitutes the retinoblastoma family of proteins. These three proteins share sequence similarity and act on cell cycle regulation, but they cannot be considered redundant, as their functions are not completely overlapping (Claudio et al., 1994) . Structurally, the proteins belonging to the retinoblastoma family can be divided in to three domains: the N-terminal domain, the T-antigen-binding region and the C-terminal domain; each with distinctive functional properties. The T-antigen-binding region can be further divided in to three subdomains: the A, the spacer and the B regions. The homology of the three proteins resides in the A/B domain.
The A/B regions are conserved throughout the family and are responsible for the binding to most of the Rbassociated proteins (Chen et al., 1995) . The spacer region has a different sequence, which renders unique each member of the retinoblastoma family. The spacer region is dispensable for pRb/p105 function, whereas this region is more conserved between p107 and pRb2/ p130 and mediates their interaction with specific cyclin/ cdk complexes (Ewen et al., 1992; Adams et al., 1996; Lacy and Whyte, 1997) .
Many biological functions exerted by the Rb proteins are owing to the integrity of the A/B domains, including regulation of growth and differentiation, transcription regulation and the interaction with cellular and viral proteins, such as the adenovirus E1A, SV40T antigen, the human papilloma virus E7 (for a review, see Kouzarides, 1995) and the HIV-1 Tat protein (De Falco et al., 2003) . Crystallographic analysis of the pRb/p105 structure reveals multiple protein-binding interfaces in the A/B domains (Lee et al., 1998) , suggesting that pRb/ p105 can simultaneously bind to several proteins, such as E2Fs and HDACs, through the E2F-binding site and the LXCXE motif-binding site, respectively. There are also some proteins that have neither binding sites that can still bind to this region (Chen and Wang, 2000) .
The A and B domains require each other to form a functional repressor motif (Chow and Dean, 1996) , because the A domain forms a scaffold to the B domain, which ensures the correct folding and the stability of the protein (Lee et al., 1998) . The integrity of these domains seems to be important for pRb/p105 function, as mutations occurring within this region appear to be tumorigenic.
The carboxyl-terminal domain of the pRb/p105 protein is less characterized, but it is critical for growth suppression (Whitaker et al., 1998) . This region contains a nuclear localization signal, which allows the shuttling of the protein from the cytoplasm to the nucleus and also permits the physical transportation to the nucleus of proteins lacking a nuclear localization signal. The C-terminal domain has an intrinsic nonspecific DNAbinding activity (Lee et al., 1987a, b) and binds to the oncoproteins c-abl and MDM2 (Whitaker et al., 1998) . Mutations occurring in the C-terminal domain determine low-penetrance retinoblastoma, suggesting the biological relevance of this domain (Bremner et al., 1997) .
Although the A/B domains and the C-terminal region of pRb/p105 mediate interaction with most of its associated proteins, there is evidence suggesting that the N-terminal region of pRb/p105 is also important for its tumor suppression function. The N-terminus is not completely characterized: like the C-terminus, this region also binds to the pocket domain. This binding seems to be important because mutations in the N-terminus of pRb/p105 abolish some functions exerted by the pocket region (Qian et al., 1992; Shen et al., 1995; Sellers et al., 1998) . In addition, the integrity of the Nterminal region seems to be necessary for the pRb/p105 protein to function; we may hypothesize that the N-terminal domain may stabilize an active pRb/p105 conformational state. Another explanation is that the N-terminal region binds to other proteins (Durfee et al., 1994; Chen et al., 1996; Sterner et al., 1995 Sterner et al., , 1996 Sterner et al., , 1998 and may therefore coordinate with other functions in pRb/p105 tumor suppression.
Role of pRb/p105 in cell cycle control: transcriptional repression
To avoid the transmission of genetic alterations and to permit cell replication only when it is required, the cell cycle is tightly regulated at the restriction points. Cells that need to enter the S phase will go through a restriction point, which is controlled by pRb/p105 during transition from early G1 to late G1/S phase (Sherr, 1996) . Passage through this point commits normal cells to DNA synthesis and cell division. Loss of control of this restriction point, as a consequence of loss of function of pRb/p105, does not interrupt cell cycle progression. Cells without proper control respond improperly to mitogenic signals, leading to abnormal cell proliferation in the neoplastic state.
The regulation of the G1/S transition by pRb/p105 has been investigated intensively. pRb/p105 binds to the E2F family of transcription factors, a group of sequence-specific DNA-binding proteins that regulate pRb2/p130: a new candidate for retinoblastoma tumor G De Falco and A Giordano transcription of genes required for entry into S phase and DNA synthesis (Dyson, 1998; Nevins, 1998) . Five of the six known members of the E2F family are able to bind to pRb/p105. This interaction functionally represses transcription, so cells are blocked in the G0/G1 phase and do not proceed through the cell cycle. This phenomenon depends on the phosphorylation status of pRb/p105, which is in its active form when hypophosphorylated and in this conformation it binds to E2Fs. The cell will remain quiescent until mitogenic signals induce pRb/p105 phosphorylation, which will inactivate it and will allow the release of the E2Fs. Several models have been postulated to explain transcriptional repression mediated by pRb/p105. In the first one, pRb/p105 represses transcription by binding to the activation domain of E2F, preventing its interaction with other factors. Alternatively, pRb/p105 may be tethered to a promoter by E2F and can simultaneously bind to another activator, thus repressing two activators at the same time (Weintraub et al., 1995) . Transcription may also be actively repressed by pRb/p105, which may carry out this function by recruiting other co-repressors (Buyse et al., 1995; Qian and Lee, 1995; Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Meloni et al., 1999) . Many of the co-repressors that facilitate active repression mediated by pRb/p105 act on chromatin. A typical example is represented by histone deacetylases (HDACs), which remove acetyl groups from the histones, rendering them more attached to DNA and giving the chromatin a less accessible configuration (Brehm et al., 1998; Kadonaga, 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . pRb/ p105 binds to HDAC1, 2 and 3 (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998; Lai et al., 1999; Dahiya et al., 2000) . pRb/p105 may recruit HDACs to DNA-bound E2F or other transcription factors and alters the chromatin structure of its target genes into a repressed-favored status. pRb/p105-mediated transcriptional repression may also involve alteration of a higher order chromatin structure, which is regulated by nucleosome-remodeling complexes (Trouche et al., 1997; Strobeck et al., 2000; Zhang et al., 2000) . Transcription regulation mediated by pRb/ p105 does not necessarily involve HDAC activity and chromatin remodeling, as pRb/p105 is able to repress transcription without the requirement of HDAC activity (Ross et al., 1999) .
Regulation of pRb/p105 activity pRb/p105 activity is regulated by phosphorylation in a cell cycle-dependent manner (Chen et al., 1989; De Caprio et al., 1989; Mihara et al., 1989) . Hypophosphorylated forms of pRb/p105 predominate in early G1 phase and reappear during M phase, whereas hyperphopshorylated forms of pRb/p105 are present from late G1 and throughout S, G2 and M phase (Chen et al., 1989; De Caprio et al., 1989; Mihara et al., 1989; Ludlow et al., 1990) . The protein contains 16 CDK recognition motifs for phosphorylation. Hypophosphorylated pRb/p105 binds to E2Fs and arrest cells in G1. When cells need to proceed through the cell cycle, inactivation of pRb/p105 occurs through several CDK-mediated phosphorylations, which start with phosphorylation mediated by the cyclin D/CDK4,6 complexes Kato et al., 1993) , occurring at the C-terminus of the protein, which then becomes able to interact with the A/B domains and to displace some of the proteins bound to the pocket region (Harbour et al., 1999) . Following cyclin D/CDK4,6 phosphorylation, associated proteins such as the HDACs that bind to pRb/p105 through their LXCXE motif are dislodged (Harbour et al., 1999) , but proteins that do not have this motif, such as the E2Fs, remain bound to pRb/p105. At this point another complex, cyclin E/CDK2, continues the phosphorylation process: the latter phosphorylation events unfold the A/B domain, thus releasing proteins bound to the pocket region, such as E2Fs, that can now bind to other complexes, allowing cell cycle progression (Harbour et al., 1999; Zhang et al., 2000) .
RB1 gene mutation in retinoblastoma
Current knowledge indicates that mutations affecting both alleles of the RB1 gene represent a prerequisite for the development of this tumor (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987a, b) , even though it is becoming evident that other genes, such as the RB1-related RB2/p130 gene, may be relevant for the disease to develop. In addition, other alterations occurring at different chromosomes may contribute to the tumorigenesis of retinoblastoma. In this section, we will summarize the current understanding about RB1 gene mutations.
Heterozygous carriers of oncogenic RB1 gene mutations show variable phenotypic expression. Patients may develop tumors in both eyes or only in one eye because of the variable expressivity. In addition, some carriers show no retinoblastoma at all because the mutations may have an incomplete penetrance. Almost all types of the RB1 gene mutations have been identified, including translocations, deletions, insertions, point mutations and epigenetic alterations (hypermethylation of the CpG-islands in the RB1 promoter region) (for a review see Lohmann and Gallie, 2004) .
The majority of germline mutations that have been identified in patients with hereditary retinoblastoma are nonsense or frameshift mutations, mostly located in the exons 1-25 of the RB1 gene (Sampieri et al., 2005) . These kinds of mutations will lead to abortive transcripts that will be degraded, leaving only the transcript of the normal allele. These mutations will have great impact on the phenotype because they completely abolish the activity of one allele, therefore the affected patients will most probably develop bilateral retinoblastoma. When a nonsense or frameshift mutation occurs in the last two exons, the transcripts may maintain some pRb2/p130: a new candidate for retinoblastoma tumor G De Falco and A Giordano residual biological activity, which will support that of the normal allele, and this will result in a milder effect in terms of phenotype. In some cases, however, carriers with frameshift or nonsense mutations will not result in the development of bilateral retinoblastoma because of mosaicism, in which not all the cells will carry the mutations and the phenotypic expression of the tumor will be less aggressive (Hall, 1988) . Point mutations in intronic or exonic regions cause aberrant splicing and abolish the biological function of pRb/p105. These splice mutations are usually associated with complete penetrance and have a great phenotypic impact. Missense mutations, on the other hand, will influence the phenotype to a variable degree depending on the residue that will be substituted and its location within the protein. Generally, when these mutations determine an alteration, that is in terms of electric charge, folding of the protein, etc., which will influence the biological activity of pRb/p105, the phenotype will be more dramatic, compared to that resulting from mutations that do not affect its biological activity. Most missense mutations determine amino-acid changes in the pocket region, whereas only a few of them have been described affecting the promoter gene of the RB1 gene (Lohmann, 1999) .
Another cause of inactivation of the pRb/p105 protein function is the hypermethylation of the CpGrich islands in the promoter region of the RB1 gene, which is normally unmethylated. These account for 10% of the retinoblastoma cases (Greger et al., 1989; Ohtani-Fujita et al., 1997; Klutz et al., 1999) and cannot be inherited, because hypermethylation represents an epigenetic event.
Role of the RB1-related RB2/p130 gene in the genesis of retinoblastoma Notwithstanding the fact that mutations of the RB1 gene are common to all retinoblastomas, much evidence indicates that loss of pRb/p105 from a developing retinal cell is not sufficient for malignancy (Di Ciommo et al., 2000) . The possibility that further mutations of other tumor suppressor genes could occur in sporadic retinoblastoma is supported by recent studies providing direct evidence that loss of pRb/p105 function leads to genomic instability and predisposes to cancer by increasing the DNA mutation rate (Zheng et al., 2002) . A possible candidate for contributing to retinoblastoma tumor formation is the RB1-related gene RB2/ p130, which encodes the pRb2/p130 protein and is a member of the retinoblastoma family of proteins. The human RB2 gene maps to chromosome 16q12.2; the mRNA is 4.6 kb in length and the gene consists of 22 exons and spans over 50 kb of genomic DNA (for a review see Claudio et al., 2002) . Inactivation of its biological function owing to genetic or epigenetic mechanisms or to physical interaction with viral oncoproteins has been described in neoplasms of different organs. In particular, an active role for pRb2/p130 has been postulated in the genesis of neoplasms of the lung (Claudio et al., 2000) , breast (Macaluso et al., 2003) , ovary (D'Andrilli et al., 2004) and non-Hodgkin's lymphomas . In addition, inactivation of its biological function owing to interaction with viral oncoproteins has also been described in mesothelioma (Mutti et al., 1998) and in AIDS-related lymphomas (De Falco et al., 2003) . An involvement for pRb2/p130 in retinoblastoma tumor development has recently been hypothesized. It has been demonstrated that pRb2/p130 expression often strongly decreases in primary retinoblastoma tumors . In addition, pRb2/p130 expression seems to correlate with the apoptotic index (AI) of the retinoblastoma samples, as tumors that do not express pRb2/ p130 have a lower AI than tumors where pRb/p130 expression is higher or normal . This suggests that pRb2/p130 may exert a proapoptotic effect on the retinoblastoma tumor samples in vivo. In addition, mutational analysis performed in both familial and sporadic retinoblastoma samples revealed that the RB2/p130 gene is often mutated in sporadic retinoblastoma, and that the mutations occur mainly in exon 1 (Tosi et al., 2005) . Hypermethylation of the CpG islands of the RB2/p130 gene has also been described as an alternative mechanism for inactivating the pRb2/p130 Figure 2 A model to explain the role of the retinoblastoma (RB)-related protein pRb2/p130 in the genesis of RB. In (a) the cell containing the M1 and M2 mutations posses a wild-type RB2/p130 gene, which leads this cell toward apoptosis. In (b) the mutated cell contains an inactive pRb2/p130, which is not able to drive cell to apoptosis. This cell will therefore proliferate (c), allowing the transmission of M1 and M2 to daughter cells. pRb2/p130: a new candidate for retinoblastoma tumor G De Falco and A Giordano protein function in these tumors (Tosi et al., 2005) . These results suggest that the RB2/p130 gene may cooperate with RB1 in contributing to retinoblastoma tumor formation. A model for pRb2/p130 function in retinoblastoma is shown in Figure 2 . A role for pRb2/p130 in retinoblastoma may be hypothesized: we may speculate that a functional pRb2/p130 is necessary to address mutated cells to apoptosis and to maintain a high AI in tumor cells. When pRb2/p130 function is lost, owing to mutations of the gene or to promoter hypermethylation, this mechanism of surveillance, which leads mutated cells to apoptosis is abolished, and this allows the transmission of genetic alterations to daughter cells. The loss of pRb2/ p130 function may therefore contribute to retinoblastoma tumor progression.
Other genetic alterations in retinoblastoma
Apart from genetic or epigenetic inactivation of the RB1 gene and allelic loss on chromosome 13q14, other recurrent genomic alterations have frequently been discovered in retinoblastoma, including the isochromosome 6p (i6p) (Horsthemke, 1992) and trisomy 1q . Tetrasomy 6p rearrangement presenting as i6p is considered to be almost exclusive to retinoblastoma (Murphree and Benedict, 1985) and additional copies of chromosome 6p have been found in 25-60% of retinoblastomas (Squire et al., 1984; Turleau et al., 1995; Oliveros and Yunis, 1995) . The presence of i6p may represent an important genetic change in the development or progression of retinoblastoma (Kusnetsova et al., 1982; Squire et al., 1984) . Additional copies of 6p might play a fundamental role in the malignancy of retinoblastoma (Cano et al., 1994) and could alter the expression of genes of the major histocompatibility complex on 6p21.3 (Horsthemke et al., 1989) . Enhanced expression of genes mapped on 6p such as TNF-a could contribute to tumor development or progression (Imbert et al., 2001) . Although i6p is the most frequent chromosomal alteration found in retinoblastomas with chromosome 6 abnormalities, it seems that only the duplication of the chromosomal region 6p21 is essential to the malignancy process of the retinoblastoma disease (Imbert et al., 2001) .
Additional genetic alterations, such as monosomy 16 or del(16q) (Pogosianz and Kuznetsova, 1986; Oliveros and Yunis, 1995) , monosomy 17 or del(17p), i(17p) (Squire et al., 1984; Oliveros and Yunis, 1995) , complete absence of pericentromeric heterochromatin on chromosome 9 (Sivakumaran et al., 1997) and loss of X or Y sex chromosomes (Pogosianz and Kuznetsova, 1986) have also been described. The presence of abnormal gene amplifications has also been discovered in retinoblastoma (Lee et al., 1984; Arheden et al., 1988; Imbert et al., 2001; Chen et al., 2002) . Genetic alterations on chromosomes 19, 20, 21, 22 and X, detected by loss of heterozygosity, occur in retinoblastoma tumor samples (Huang et al., 2003) .
Conclusions
Tumor suppressor gene cloning has improved our knowledge and understanding of the molecular mechanisms of cancer development. Genetic alterations of the prototype of tumor suppressors, the RB1 gene, represent the molecular hallmark of retinoblastoma, the most common childhood malignancy. Identification of the molecular mechanisms of inactivation of its biological function has shed some light on the genesis of cancer in general. Recent discoveries have pointed out the role of additional genetic or epigenetic alterations of other markers that may be involved in retinoblastoma tumor formation. Among these, a role for the RB2/p130 gene in retinoblastoma tumor formation has been emerging recently, as mutations of this gene have been found in retinoblastoma primary tumors. In addition, the inactivation of its function correlates with a lower AI of tumor cells, suggesting that its inactivation may promote tumor progression by acting on the programmed cell death pathway. Additional genetic or epigenetic alterations occurring on other chromosomes also seen to be relevant for a retinoblastoma tumor to occur. Further studies to completely elucidate the molecular mechanisms underlying retinoblastoma tumorigenesis will be of help in designing new targets and novel therapeutic approaches to cure this disease.
